Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of the proposed study is to test the effect of Licorice Root Extract- Licogen on postmenopausal symptoms in postmenopausal women. Specifically, the study will also test the effect of the licorice extract on vaginal dryness.
Condition | Intervention | Phase |
---|---|---|
Postmenopausal Symptoms Vaginal Dryness |
Dietary Supplement: Calmera-Licorice Root Extract (Licogen) |
Phase 1 Phase 2 |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms |
- A beneficial effect of the licorice extract on postmenopausal symptoms (vasomotor symptoms, and nocturnal episodes) in symptomatic postmenopausal women [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]
This outcome will be measured by:
a diary in which she should report daily. The reporting would be for 3 parameters: number of hot flushes per day, wakefull night episodes and nocturnal sweating measured by Greens Climateric Scale
- A beneficial effect of the licorice extract on vaginal complaints in symptomatic postmenopausal women [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]this objective will be measured by Pap Smear, Vaginal Ultra sound and vaginal PH
Estimated Enrollment: | 120 |
Study Start Date: | September 2010 |
Estimated Study Completion Date: | September 2011 |
Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
-
Dietary Supplement: Calmera-Licorice Root Extract (Licogen)
The estrogenic properties of glabridin, the major isoflavan in licorice root, were tested in view of the resemblance of its structure and lipophilicity to those of estradiol. The results indicate that glabridin is a phytoestrogen, binding to the human estrogen receptor and stimulating creatine kinase activity in rat uterus, epiphyseal cartilage, diaphyseal bone, aorta, and left ventricle of the heart. The stimulatory effects of 2.5-25 mg/animal glabridin were similar to those of 5 mg/animal estradiol. Chemical modification of glabridin showed that the position of the hydroxyl groups has a significant role in binding to the human estrogen receptor and in proliferation-inducing activity. Glabridin was found to be three to four times more active than 2*-O-methylglabridin and 4*-O-methylglabridin, and both derivatives were more active than 2*,4*- O-methylglabridin. The effect of increasing concentrations of glabridin on the growth of breast tumor cells was biphasic. Glabridin showed an estrogen receptor-dependent, growth-promoting effect at low concentrations (10 nM-10 mM) and estrogen receptor-independent antiproliferative activity at concentrations of >15 mM. This is the first study to indicate that isoflavans have estrogen-like activities. Glabridin and its derivatives exhibited varying degrees of estrogen receptor agonism in different tests and demonstrated growth-inhibitory actions on breast cancer cells.
Ages Eligible for Study: | 45 Years to 60 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women between the ages 45-60,
- Who are post-menopausal (proved by a laboratory test of FSH > 30 International units),
- Patients who report having post-menopausal symptoms, who report having, at least 5-7 hot flushes per day, as well as wakeful night episodes and nocturnal sweating (measured by Greenscale or Cooperman Index).
Exclusion Criteria:
- Female patients who are outside the age boundaries of 45-60,
- Have FSH <30
- Patients who presently have cancer of any kind,
- Patients that are on any other treatment for relieving post-menopausal symptoms
- Patients who have contraindication to Licorice.
Contact: Boris Kaplan, MD | 972-3-9377534 | bkaplan@clalit.org.il |
Israel | |
Rabin Medical Center | Not yet recruiting |
Petah Tikva, Israel | |
Contact: Boris Kaplan, MD 972-3-9377534 bkaplan@clalit.org.il | |
Principal Investigator: Boris Kaplan, MD |
Principal Investigator: | Boris Kaplan, MD | Rabin Medical Center |
No publications provided
Responsible Party: | Nir Kedem, F&C Licorice Ltd |
ClinicalTrials.gov Identifier: | NCT01170195 History of Changes |
Other Study ID Numbers: | 5459 |
Study First Received: | July 26, 2010 |
Last Updated: | July 26, 2010 |
Health Authority: | Israel: Ethics Commission |
Keywords provided by F&C Licorice Ltd:
Postmenopausal licorice vaginal complaints |
ClinicalTrials.gov processed this record on October 17, 2012